ARTL Artelo Biosciences Inc.: Enterprise Value-to-Revenue Ratio

Public company logo of Artelo Biosciences Inc. (ARTL)

The stable operation of Artelo Biosciences contract manufacturing confirms the technological maturity of the business. The EV/Sales ratio clearly captures the company's market value relative to sales, where the indicator stands at 0.00. Leading biochemists, attracted by RSU options, drive this success. Furthermore, demand for cancer therapy remains independent of macroeconomics, rendering the company resilient to market cycles.

Artelo Biosciences, Inc. (ARTL): Company Value to Revenue from 11/23/2025 to 11/20/2026

Artelo Biosciences Inc. - analytical breakdowns and key metrics (ARTL)

Initial company analysis:ARTL, Artelo
Flagship merchandise of Artelo Biosciences, Inc.

Artelo Biosciences strategic alliances in the cannabinoid sector define the company's EV/Revenue trajectory, reflecting market expectations for future M&A. This indicator compares the total Enterprise Value (EV), including debt and subtracting cash, with sales volume, allowing for an assessment of whether the asset is overvalued or undervalued regardless of the capital structure.